No Data
Express News | [Change Report] CANTOR FITZGERALD reports a decrease in shareholding percentage of Anjess (4563.JP) stock to 25.82%.
Stocks that moved the previous day part 2. Aiz, Eurasia Travel Agency, Japan Oxygen HD, etc.
Stock name <code> 5-day closing price ⇒ compared to the previous day China Electric Power <9504> 902.0 -34.7 Major electrical utilities stocks are generally under a sell bias. Japan Oxygen HD <4091> 4332 -135 morgan stanley MUFG Securities has lowered its target stock price. Rakuten Bank <5838> 4110 -126 The speculation about the Bank of Japan postponing interest rate hikes in December is growing stronger. Kasumigaseki Capital <3498> 12390 -400 Approaching the 25-day moving average level, selling on the rebound may be dominant. Tohoku Electric Power <9506>
Active and newly listed stocks during the morning session.
*Osaka Soda <4046> 1639 +220 The movement to revise the company follows the briefing session from the previous day. *Keeper Technology <6036> 4605 +410 Existing stores in November show a positive recovery for the first time in two months. *Ceres <3696> 2734 +194 The price of bitcoin reached 0.1 million dollars etc. *Kawasaki Heavy Industries <7012> 6726 +424 Continued interest as a key player in defense-related industries. *Kumagai Gumi <1861> 4070 +250 Nomura Securities has upgraded its investment rating.
Strong performance, supported by rising U.S. stocks [emerging markets individual stock global strategy]
[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to show a steady performance. In the U.S. stock market on the 4th, the Dow Jones Industrial Average rose by 308.51 points (+0.69%) to 45,014.04, rebounding for the first time in three days. This was supported by the confirmation of robust job growth in the private sector’s November ADP employment statistics and a decline in long-term interest rates, which bolstered stock prices. Additionally, towards the end of the session, Federal Reserve Chairman Powell expressed an optimistic outlook for the economy in an interview, and the Federal Reserve released...
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive IDSMB Recommendation to Move to the High-Dose Cohort for AV001-004 Phase 2a Study
AnGes --- HGF gene therapy product "Colatagen" presented at the American College of Cardiology academic session.
Anges <4563> announced on the 19th that it reported the clinical trial results of the HGF gene therapy product "Colategen" at the American Heart Association's scientific session, scheduled for November 18, 2024. The report on the results of the late-stage Phase II clinical trial of Colategen (LEGEND1 trial) was selected for the Featured Science Session at the American Heart Association conference held in Chicago, Illinois, USA, from November 16-18, 2024.